Procept Biorobotics vs Staar Surgical
Procept Biorobotics is the larger business, with $308m of revenue in fiscal 2025 against $239m for Staar Surgical (1.3 times as much). Procept Biorobotics grew faster (37.2% against -23.7%). Procept Biorobotics kept more of each dollar of sales as profit: a net margin of -31.0% against -33.6%. Staar Surgical carries less debt relative to equity (0.0% against 14.2%).
| Latest fiscal year | Procept BioroboticsPRCT, 2025 | Staar SurgicalSTAA, 2025 |
|---|---|---|
| Revenue | $308m | $239m |
| Revenue growth | 37.2% | -23.7% |
| Net income | −$95.6m | −$80.4m |
| Operating margin | -33.7% | -38.3% |
| Net margin | -31.0% | -33.6% |
| Return on equity | -24.9% | -21.7% |
| Free cash flow | −$58.3m | −$40.0m |
| Cash | $287m | $153m |
| Total debt | $52.0m | $0 |
| Debt to equity | 14.2% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | $6.5m |
| Employees | 888 | 957 |
| Market value | $1.16bn | $1.25bn |
| Price vs our value range | — | — |
| Moat score | 25 (Weak) | 34 (Weak) |
| Insider trades, 12 months | 8 buys, 14 sales | 21 buys, 0 sales |